Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study
Standard
Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. / Warnholtz, Ascan; Wild, Philipp; Ostad, Mir Abolfazl; Elsner, Veronika; Stieber, Fabian; Schinzel, Reinhard; Walter, Ulrich; Peetz, Dirk; Lackner, Karl; Blankenberg, Stefan; Munzel, Thomas.
in: ATHEROSCLEROSIS, Jahrgang 204, Nr. 1, 05.2009, S. 216-221.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study
AU - Warnholtz, Ascan
AU - Wild, Philipp
AU - Ostad, Mir Abolfazl
AU - Elsner, Veronika
AU - Stieber, Fabian
AU - Schinzel, Reinhard
AU - Walter, Ulrich
AU - Peetz, Dirk
AU - Lackner, Karl
AU - Blankenberg, Stefan
AU - Munzel, Thomas
PY - 2009/5
Y1 - 2009/5
N2 - High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentrations were measured before and after treatment. Triglycerides (P=0.013), low-density-lipoprotein-cholesterol (LDL-C) (P=0.013) and HDL-C (P<0.0001) were altered by N compared to C. Niacin treatment was without effect on FMD or NMD, respectively, compared to placebo. However, post-hoc subgroup analysis revealed an improvement in FMD in patients with low HDL-C at baseline (absolute change in FMD (mean+/-S.D.) N: +3.25+/-3.88%, C: +1.03+/-2.71% in low tertile HDL-C
AB - High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentrations were measured before and after treatment. Triglycerides (P=0.013), low-density-lipoprotein-cholesterol (LDL-C) (P=0.013) and HDL-C (P<0.0001) were altered by N compared to C. Niacin treatment was without effect on FMD or NMD, respectively, compared to placebo. However, post-hoc subgroup analysis revealed an improvement in FMD in patients with low HDL-C at baseline (absolute change in FMD (mean+/-S.D.) N: +3.25+/-3.88%, C: +1.03+/-2.71% in low tertile HDL-C
KW - Administration, Oral
KW - Aged
KW - Biomarkers/blood
KW - Blood Glucose/drug effects
KW - Brachial Artery/diagnostic imaging
KW - Cell Adhesion Molecules/blood
KW - Cholesterol, HDL/blood
KW - Cholesterol, LDL/blood
KW - Coronary Artery Disease/blood
KW - Delayed-Action Preparations
KW - Double-Blind Method
KW - Endothelium, Vascular/drug effects
KW - Female
KW - Humans
KW - Male
KW - Microfilament Proteins/blood
KW - Middle Aged
KW - Niacin/administration & dosage
KW - Nitroglycerin/administration & dosage
KW - Phosphoproteins/blood
KW - Phosphorylation
KW - Prospective Studies
KW - Treatment Outcome
KW - Triglycerides/blood
KW - Ultrasonography
KW - Vasodilation/drug effects
KW - Vasodilator Agents/administration & dosage
U2 - 10.1016/j.atherosclerosis.2008.08.003
DO - 10.1016/j.atherosclerosis.2008.08.003
M3 - SCORING: Journal article
C2 - 18822413
VL - 204
SP - 216
EP - 221
JO - ATHEROSCLEROSIS
JF - ATHEROSCLEROSIS
SN - 0021-9150
IS - 1
ER -